{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:09:49Z","timestamp":1781201389119,"version":"3.54.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"DOI":"10.7759\/cureus.87133","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T21:03:48Z","timestamp":1751403828000},"source":"Crossref","is-referenced-by-count":1,"title":["Hemophagocytic Lymphohistiocytosis and the Liver Masquerade"],"prefix":"10.7759","author":[{"given":"Hadasa","family":"Banayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Haoson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Hemophagocytic lymphohistiocytosis (HLH)","author":"Lipton JM","year":"2024","unstructured":"Lipton JM, Levy CF. Hemophagocytic lymphohistiocytosis (HLH). Merck Manual Professional Version. Merck & Co., Inc, Rahway, NJ; 2024."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041696","article-title":"Mortality and associated causes in hemophagocytic lymphohistiocytosis: A multiple-cause-of-death analysis in France","volume":"12","author":"La Marle S","year":"2023","unstructured":"La Marle S, Richard-Colmant G, Fauvernier M, Ghesqui\u00e8res H, Hot A, S\u00e8ve P, Jamilloux Y. Mortality and associated causes in hemophagocytic lymphohistiocytosis: A multiple-cause-of-death analysis in France. J Clin Med. 2023, 12:1696. 10.3390\/jcm12041696","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2021.05.003","article-title":"Hemophagocytic lymphohistiocytosis: Presentation and outcome of twenty-one patients at a single institution","volume":"44","author":"Rodrigues JB","year":"2022","unstructured":"Rodrigues JB, Nasr BP, Cypriano MD. Hemophagocytic lymphohistiocytosis: Presentation and outcome of twenty-one patients at a single institution. Hematol Transfus Cell Ther. 2022, 44:485-90. 10.1016\/j.htct.2021.05.003","journal-title":"Hematol Transfus Cell Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00366-5","article-title":"Malignancy-associated haemophagocytic lymphohistiocytosis","volume":"9","author":"Setiadi A","year":"2022","unstructured":"Setiadi A, Zoref-Lorenz A, Lee CY, Jordan MB, Chen LYC. Malignancy-associated haemophagocytic lymphohistiocytosis. Lancet Haematol. 2022, 9:e217-27. 10.1016\/S2352-3026(21)00366-5","journal-title":"Lancet Haematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04781-4","article-title":"Serum sCD25\/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation","volume":"149","author":"Zou H","year":"2023","unstructured":"Zou H, He L, Hue Z, et al.. Serum sCD25\/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation. J Cancer Res Clin Oncol. 2023, 149:8521-33. 10.1007\/s00432-023-04781-4","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2007.05.001","article-title":"Hemophagocytic syndromes","volume":"21","author":"Janka GE","year":"2007","unstructured":"Janka GE. Hemophagocytic syndromes. Blood Rev. 2007, 21:245-53. 10.1016\/j.blre.2007.05.001","journal-title":"Blood Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter JI","year":"2007","unstructured":"Henter JI, Horne A, Aric\u00f3 M, et al.. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007, 48:124-31. 10.1002\/pbc.21039","journal-title":"Pediatr Blood Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43909-w","article-title":"Clinical characteristics of liver failure with hemophagocytic lymphohistiocytosis","volume":"9","author":"Dong J","year":"2019","unstructured":"Dong J, Xie F, Jia L, et al.. Clinical characteristics of liver failure with hemophagocytic lymphohistiocytosis. Sci Rep. 2019, 9:8125. 10.1038\/s41598-019-43909-w","journal-title":"Sci Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2006.01228.x","article-title":"Definition and management of anemia in patients infected with hepatitis C virus","volume":"26","author":"McHutchison JG","year":"2006","unstructured":"McHutchison JG, Manns MP, Longo DL. Definition and management of anemia in patients infected with hepatitis C virus. Liver Int. 2006, 26:389-98. 10.1111\/j.1478-3231.2006.01228.x","journal-title":"Liver Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2020.10.001","article-title":"Hepatitis-associated aplastic anemia","volume":"15","author":"Alshaibani A","year":"2022","unstructured":"Alshaibani A, Dufour C, Risitano A, de Latour R, Aljurf M. Hepatitis-associated aplastic anemia. Hematol Oncol Stem Cell Ther. 2022, 15:8-12. 10.1016\/j.hemonc.2020.10.001","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.4653","article-title":"Spectrum of anemia associated with chronic liver disease","volume":"15","author":"Gonzalez-Casas R","year":"2009","unstructured":"Gonzalez-Casas R, Jones EA, Moreno-Otero R. Spectrum of anemia associated with chronic liver disease. World J Gastroenterol. 2009, 15:4653-8. 10.3748\/wjg.15.4653","journal-title":"World J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.18203\/2349-3933.ijam20160494","article-title":"Hematological spectrum in patients with alcoholic liver cirrhosis: A model of end-stage liver disease score based approach","volume":"3","author":"Jain D","year":"2016","unstructured":"Jain D, Aggarwal HK, Rao A, Dahiya S, Singla S. Hematological spectrum in patients with alcoholic liver cirrhosis: A model of end-stage liver disease score based approach. Int J Adv Med. 2016, 3:234-40. 10.18203\/2349-3933.ijam20160494","journal-title":"Int J Adv Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1994.tb00088.x","article-title":"Carbohydrate-deficient transferrin and other markers of high alcohol consumption: A study of 502 patients admitted consecutively to a medical department","volume":"18","author":"Bell H","year":"1994","unstructured":"Bell H, Tallaksen CM, Try K, Haug E. Carbohydrate-deficient transferrin and other markers of high alcohol consumption: A study of 502 patients admitted consecutively to a medical department. Alcohol Clin Exp Res. 1994, 18:1103-8. 10.1111\/j.1530-0277.1994.tb00088.x","journal-title":"Alcohol Clin Exp Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-602607","article-title":"Marked hyperferritinemia does not predict for HLH in the adult population","volume":"125","author":"Schram AM","year":"2015","unstructured":"Schram AM, Campigotto F, Mullally A, Fogerty A, Massarotti E, Neuberg D, Berliner N. Marked hyperferritinemia does not predict for HLH in the adult population. Blood. 2015, 125:1548-52. 10.1182\/blood-2014-10-602607","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/hmer.s4393","article-title":"A high prevalence of extreme hyperferritinemia in acute hepatitis patients","volume":"1","author":"Kotoh K","year":"2009","unstructured":"Kotoh K, Ueda A, Tanaka M, et al.. A high prevalence of extreme hyperferritinemia in acute hepatitis patients. Hepat Med. 2009, 1:1-8. 10.2147\/hmer.s4393","journal-title":"Hepat Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-021-02859-x","article-title":"Reliability of visual assessment of neonatal jaundice among neonates of black descent: A cross-sectional study from Tanzania","volume":"21","author":"Dionis I","year":"2021","unstructured":"Dionis I, Chillo O, Bwire GM, Ulomi C, Kilonzi M, Balandya E. Reliability of visual assessment of neonatal jaundice among neonates of black descent: A cross-sectional study from Tanzania. BMC Pediatr. 2021, 21:383. 10.1186\/s12887-021-02859-x","journal-title":"BMC Pediatr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1159\/000518826","article-title":"Influence of ethnicities and skin color variations in different populations: A review","volume":"35","author":"Naik PP","year":"2022","unstructured":"Naik PP, Farrukh SN. Influence of ethnicities and skin color variations in different populations: A review. Skin Pharmacol Physiol. 2022, 35:65-76. 10.1159\/000518826","journal-title":"Skin Pharmacol Physiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/293798-hemophagocytic-lymphohistiocytosis-and-the-liver-masquerade","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T21:03:48Z","timestamp":1751403828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/293798-hemophagocytic-lymphohistiocytosis-and-the-liver-masquerade"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.87133","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}